1.88
-0.18(-8.74%)
Currency In USD
Address
35 Cambridgepark Drive
Boston, MA 02140
United States of America
Phone
617 221 9059
Sector
Healthcare
Industry
Biotechnology
Employees
44
First IPO Date
October 08, 2021
| Name | Title | Pay | Year Born |
| Lara S. Sullivan | Chief Executive Officer, President, Chief Medical Officer & Director | 1.06M | N/A |
| Donna Regalado | Head of Human Resources | 0 | N/A |
| Balu N. Balasubramanian | Interim Chief Technology Officer | 0 | N/A |
| Charles T. Gombar | Senior Vice President of Portfolio & Program Management | 0 | N/A |
| Jan Pinkas | Chief Scientific Officer | 0 | N/A |
| Michael Bui | Head of Global Regulatory Affairs | 0 | N/A |
| Supriya Roth | Head of Commercial Development | 0 | N/A |
| Alex Kane | Senior Vice President of Investor Relations & Capital Markets | 0 | N/A |
| Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer | 0 | 1980 |
| Stephen T. Worsley | Senior VP & Chief Business Officer | 0 | 1964 |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
